CJC-1295 No DAC + Ipamorelin

CJC-1295 (No DAC) + Ipamorelin – 10 mg

For In Vitro Research Use Only
Not for Human or Veterinary Application

Product Overview

This product is a co-lyophilized research blend combining CJC-1295 without DAC (Drug Affinity Complex) at 5 mg and Ipamorelin at 5 mg in a single lyophilized preparation. CJC-1295 (No DAC) is a synthetic 30-amino acid analog of GHRH(1-29) and a GHRHR agonist, while Ipamorelin is a synthetic pentapeptide ghrelin mimetic and selective GH secretagogue receptor (GHSR-1a) agonist. The combination is studied as a dual-mechanism pharmacological tool for investigating synergistic GH pulse stimulation via simultaneous GHRHR and GHSR-1a receptor activation in pituitary and hypothalamic cell research models.

Specifications

• Quantity: 10 mg total (CJC-1295 No DAC: 5 mg | Ipamorelin: 5 mg)

• Form: Lyophilized Powder (co-formulated blend)

• CJC-1295 (No DAC) CAS: 863288-34-0 | MW ~3,367.1 Da

• Ipamorelin sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2 | CAS 170851-70-4 | MW ~711.9 Da

• Purity: ≥99.4% per component (third-party verified)

• Storage: -20°C long-term; 4°C short-term (use within 4 weeks of reconstitution)

Research Context

CJC-1295 (No DAC) activates the GHRH receptor (GHRHR) via Gαs/cAMP/PKA signaling, stimulating GH gene transcription and secretion from anterior pituitary somatotroph cells in a manner analogous to endogenous GHRH, but without the DAC modification that confers extended albumin-binding half-life in the DAC-containing variant. Ipamorelin is a highly selective GHSR-1a (ghrelin receptor) agonist with a pentapeptide structure that activates GH secretagogue receptor signaling through a distinct Gαq/IP3/Ca2+ pathway — mechanistically complementary to GHRHR-mediated stimulation. The combination is studied for synergistic or additive effects on GH secretion amplitude and pulse frequency in pituitary cell culture systems. Ipamorelin’s selectivity for GHSR-1a over ACTH, cortisol, and prolactin-releasing pathways makes this blend a research tool of interest in studies requiring selective GH axis modulation without broad hypothalamic-pituitary axis activation.

Intended Use

This compound is intended strictly for in vitro laboratory research by qualified professionals.
It is not approved for:

• Human use

• Veterinary use

• Food, drug, diagnostic, or cosmetic applications

Regulatory Disclaimer

• This compound has not been evaluated by the U.S. Food and Drug Administration (FDA).

• It is sold strictly as a research material with no medical or therapeutic claims.

• All handling and use must comply with applicable institutional, local, state, and federal regulations.

Terms of Sale

By purchasing from Axis Peptide Labs, the buyer confirms that they are a qualified researcher, laboratory, or institution and acknowledge that the product is for research use only.

• All sales are final.

• The purchaser assumes full responsibility for compliant handling, storage, and use.

• Resale for human consumption is strictly prohibited.